glp-1 news today october 20 2025 weight loss drugs leave users low on key nutrients, study finds Dr. Blum and our patient

Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents the newest class of weight loss medications with remarkable clinical trial results from the SURMOUNT studies (Jastreboff et al., NEJM, 2022)

Discuss persistent or severe reflux with your doctor before making changes to your PlexusDx semaglutide regimen

doi: 10.1507/endocrj.k09e-117

Extended absence of bowel movements can lead to fecal impaction, a condition where hardened stool becomes lodged in the rectum or colon and cannot be passed without medical intervention

SS: Conceptualization, Investigation, Supervision, Writing review & editing

DOI: 10.1016/j.clnu.2022.10.015